Cagrilintide vs Survodutide.

Cagrilintide (development code AM833) is a long-acting, once-weekly synthetic analogue of the pancreatic hormone amylin, developed by Novo Nordisk. It is a "dual amylin and calcitonin receptor agonist" (DACRA)-class peptide engineered with a lipidation (fatty-acid acylation) that prolongs its half-life, and is being investigated for chronic weight management in adults with overweight or obesity, both as a monotherapy and as the amylin component of the fixed-dose combination CagriSema (with semaglutide).

Survodutide (BI 456906) is an investigational once-weekly injectable peptide that activates two gut-hormone receptors at once: the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). It is being co-developed by Boehringer Ingelheim and Zealand Pharma as a candidate treatment for obesity and for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). It is not an approved medicine and is available only within regulated clinical trials. The dual-receptor design is intended to combine appetite and blood-sugar effects with an added push on energy expenditure and liver-fat handling.

Native amylin is co-secreted with insulin from pancreatic beta cells and reduces food intake by promoting meal-ending satiety, slowing gastric emptying, and suppressing glucagon. Cagrilintide mimics this by activating amylin and calcitonin receptors, which are heterodimers of the calcitonin receptor with receptor-activity-modifying proteins (RAMPs). Preclinical work in RAMP1/RAMP3 knockout mice (eBioMedicine, 2025) indicates cagrilintide's weight-lowering effect is mediated largely through brain amylin receptors 1 and 3 in hindbrain and hypothalamic circuits that govern appetite. Because amylin signaling is mechanistically distinct from GLP-1, combining the two (as in CagriSema) is intended to engage complementary satiety pathways and produce additive weight loss.

As a GLP-1 receptor agonist, survodutide slows gastric emptying, enhances glucose-dependent insulin secretion, and reduces appetite through central pathways. Its distinguishing feature is simultaneous agonism of the glucagon receptor, which in this metabolic context is thought to raise energy expenditure and promote hepatic fat mobilization. This balanced dual agonism aims to produce greater weight loss and liver benefit than GLP-1 activation alone. The molecule is engineered for a long half-life to permit weekly subcutaneous dosing.

Human data are now substantial for the combination and growing for monotherapy. The pivotal phase 3 REDEFINE 1 trial in over 3,400 adults with overweight/obesity without diabetes (NEJM 2025, PMID 40544433) reported mean weight loss of roughly 20.4% with CagriSema, 11.8% with cagrilintide monotherapy, 14.9% with semaglutide, and about 3% with placebo at 68 weeks; cagrilintide thus produced clinically meaningful weight loss on its own, though less than the combination. REDEFINE 2 studied CagriSema in type 2 diabetes, and additional REDEFINE/REIMAGINE program trials (e.g., REIMAGINE 2 in The Lancet Diabetes & Endocrinology, 2026) extend the dataset. The brain-receptor mechanism evidence (eBioMedicine, PMID 40609154) is preclinical (mouse), so the molecular target attribution should not be read as proven in humans; most large efficacy data describe the semaglutide combination rather than cagrilintide alone.

The core efficacy dataset for survodutide comes from a randomised, double-blind, placebo-controlled, dose-finding Phase 2 trial published in The Lancet Diabetes & Endocrinology (2024) and sponsored by Boehringer Ingelheim, in which 386 adults with obesity received survodutide (0.6-4.8 mg) or placebo over 46 weeks. Mean body-weight reductions were roughly -6.2%, -12.5%, -13.2% and -14.9% across ascending doses versus -2.8% for placebo under the treatment-policy analysis, with weight loss of nearly 19% among participants who reached and stayed on the highest dose. Weight loss was dose-dependent and had not clearly plateaued by week 46, suggesting further potential with longer treatment. The design limits interpretation: a single dose-finding study, placebo rather than active comparator, a 46 week horizon, and body weight as a surrogate rather than a clinical outcome. Survodutide has also been studied in a Phase 2 MASH trial, where it improved liver histology endpoints relative to placebo, and a later mediation analysis published in Hepatology examined how much of the liver benefit tracked with weight reduction and how much appeared independent of it. Larger Phase 3 obesity and MASH programs are underway to confirm efficacy and long-term safety; results reported so far include a Phase 3 trial of once-weekly survodutide in adults with obesity in the New England Journal of Medicine and the SYNCHRONIZE-MASLD Phase 3 trial in adults with obesity and metabolic dysfunction-associated steatotic liver disease in Nature Medicine. Several gaps remain explicit. There is no dedicated cardiovascular outcome trial result for survodutide, unlike semaglutide, which has published cardiovascular outcome data. There are no head-to-head randomised comparisons against semaglutide or tirzepatide, both of which have completed registrational programs and regulatory approval, so cross-trial percentage comparisons are not reliable. There is no multi-year durability, weight-regain, or paediatric evidence. As an investigational agent, its benefit-risk profile is not yet established.

In the REDEFINE program the safety profile of cagrilintide and CagriSema was reported as broadly consistent with incretin/amylin-based therapies, with predominantly mild-to-moderate gastrointestinal effects (nausea, vomiting, diarrhea, constipation) as the most common adverse events, generally most pronounced during dose escalation. Long-term safety, cardiovascular outcomes, and the safety of cagrilintide as a standalone therapy are not yet fully characterized in published phase 3 data, and head-to-head long-term comparisons remain limited. As an investigational agent, cagrilintide has no established safety profile for use outside of controlled clinical trials; material sold as research-only "cagrilintide" is not a regulated medicine and carries unknown identity, purity, and contamination risks.

In the Phase 2 obesity trial, adverse events were common and predominantly gastrointestinal, including nausea, vomiting and diarrhoea, occurring far more often than with placebo. These effects were most frequent during dose escalation, consistent with the GLP-1 drug class. A slower titration schedule was explored to improve tolerability. Beyond the trial data, the incretin class carries recognised issues that a regulator will expect to see characterised: gallbladder and biliary events, reported cases of pancreatitis, retained gastric contents relevant to sedation and anaesthesia, loss of lean mass alongside fat mass, and rodent thyroid C-cell findings that have shaped labelling for several agents. Glucagon receptor agonism adds its own questions, notably heart rate increases and hepatic parameters, which is why trials of this class typically require scheduled liver chemistry, heart rate and blood pressure monitoring, contraception and pregnancy exclusion, and structured stopping rules for intolerable gastrointestinal effects. Because survodutide is still in trials, rare or long-term risks remain incompletely characterized, and it should only be used under clinical-trial supervision. There is also a supply problem outside that setting: survodutide is not commercially manufactured for patients, so any material offered through grey-market research-chemical channels has no verified identity, potency, purity or sterility, no cold-chain guarantee, and no adverse-event reporting pathway. Contamination and mislabelling in that supply chain are documented concerns for peptides generally, and they compound the fact that the underlying molecule has no established safety profile in unsupervised use.

Cagrilintide is investigational and not approved by the FDA as a standalone drug. Novo Nordisk submitted an NDA for the CagriSema combination (cagrilintide plus semaglutide) for weight management on December 18, 2025; as of mid-2026 it remains under FDA review and is not yet approved.

Survodutide is an investigational drug and has not been approved by the FDA, EMA, or any major regulator for any indication. It carries an FDA Breakthrough Therapy designation for MASH with fibrosis. Any use outside a registered clinical trial is unapproved.